Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01258855 · ClinicalTrials.gov registry record · Phase 2
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT01258855: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01258855 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01258855, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Aldesleukin may stimulate the white blood cells to kill cancer. Ziv-aflibercept may stop the growth of melanoma by blocking blood flow to the tumor. It is not yet known whether aldesleukin is more effective with or without ziv-aflibercept in treating melanoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Aldesleukin
- BIOLOGICAL Ziv-Aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2011-01-18 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01258855
The ClinicalTrials.gov registry entry for NCT01258855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01258855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01258855 about?
NCT01258855 is a clinical study titled "Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery". This randomized phase II trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Aldesleukin may stimulate the white blood cells to kill cancer. Ziv-aflibercept may stop the growth of melanoma by bloc...
What is the current status of trial NCT01258855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2011-01-18. Estimated completion is 2018-03-29.
What interventions are being tested in trial NCT01258855?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Aldesleukin (BIOLOGICAL), Ziv-Aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT01258855?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.